Tenofovir

"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Descriptor ID	D000068698
MeSH Number(s)	D02.705.429.906 D03.633.100.759.138.881
Concept/Terms	Tenofovir Tenofovir 9-(2-Phosphonylmethoxypropyl)adenine 9-PMPA (tenofovir) 9-(2-Phosphonomethoxypropyl)adenine 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer Tenofovir Disoproxil Fumarate Tenofovir Disoproxil Fumarate Disoproxil Fumarate, Tenofovir Fumarate, Tenofovir Disoproxil Tenofovir Disoproxil Tenofovir Disoproxil Disoproxil, Tenofovir 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 (R)-9-(2-phosphonylmethoxypropyl)adenine Viread Viread

Below are MeSH descriptors whose meaning is more general than "Tenofovir".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organophosphorus Compounds [D02.705]
Organophosphonates [D02.705.429]
Tenofovir [D02.705.429.906]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Purines [D03.633.100.759]
Adenine [D03.633.100.759.138]
Tenofovir [D03.633.100.759.138.881]

Below are MeSH descriptors whose meaning is related to "Tenofovir".

Below are MeSH descriptors whose meaning is more specific than "Tenofovir".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.

Bar chart showing 10 publications over 7 distinct years, with a maximum of 2 publications in 2012 and 2015 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2012	0	2	2
2013	0	1	1
2015	1	1	2
2016	0	1	1
2017	0	1	1
2018	1	0	1
2019	0	2	2

Below are the most recent publications written about "Tenofovir" by people in Profiles.

Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions. Drugs. 2019 Aug; 79(12):1263-1276.

View in: PubMed
Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372.

View in: PubMed
Michal JL, Rab S, Patel M, Kyle AW, Miller LS, Easley KA, Kalapila AG. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic. AIDS Res Hum Retroviruses. 2018 08; 34(8):690-698.

View in: PubMed
Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. Medicine (Baltimore). 2017 Sep; 96(36):e8046.

View in: PubMed
Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016 07 31; 30(12):1973-83.

View in: PubMed
Cáceres CF, Koechlin F, Goicochea P, Sow PS, O'Reilly KR, Mayer KH, Godfrey-Faussett P. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc. 2015; 18(4 Suppl 3):19949.

View in: PubMed
Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11.

View in: PubMed
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov; 13(11):927-35.

View in: PubMed
Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, Krishnasami Z, Willig JH, Martin JN, Moore RD, Eron JJ, Kitahata MM. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012 Sep 24; 26(15):1907-15.

View in: PubMed
Rokas KE, Bookstaver PB, Shamroe CL, Sutton SS, Millisor VE, Bryant JE, Weissman SB. Role of raltegravir in HIV-1 management. Ann Pharmacother. 2012 Apr; 46(4):578-89.

View in: PubMed

People

Explore

Similar Concepts

Top Journals